Recent Advances in Biologics, Microbiome Technologies, Intelligent Drug Discovery and Biomanufacturing Technologies

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides insights across recent technology advances across cell & gene therapies, immunotherapies, intelligent drug discovery approaches, automated biomanufacturing and microbiome sciences. The TOE also encompasses recent developments in proteomics, drug delivery formulations and non-invasive biomarkers for Alzheimer’s disease.

The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Keywords: Epigenetics, Gene Silencing, Gene Therapy, Monoclonal Antibody, Bispecific Antibody, Bispecific T Cell Engager, Thrombocytopenia, Drug Discovery, T-Cell Therapy, Immunotherapy, Cancer, Cell & Gene Therapy, Intelligent Drug Discovery, Robotic Biomanufacturing, Intelligent Protein Expression, Vaccine Development, Renal Therapy, Autoimmune Diseases, Proteomics, Single Molecule Protein Analysis, Microbiome, Biotics, Probiotics, Synbiotics, Postbiotics, Prebiotics, Food & Beverage, RNA Therapies, Alzheimer’s Disease, Blood-based Biomarkers, Nanoparticle Drug Delivery, Microbial Dysbiosis